Solaxa Inc. Appoints Amy Chappel, MD, FAAN as Chief Medical Officer
Bethesda, MD; January 1, 2024 – Solaxa Inc. announces that Amy Chappell, MD, FAAN, has joined the company in the role of Chief Medical Officer (CMO). A board-certified neurologist with special competency in child neurology, Dr. Chappell is a pharmaceutical executive and neuroscientist with both strategic and operational experience across all phases of drug development. She spent over 25 years with Eli Lilly and Company in medical leadership roles. She then was a VP of Neuroscience for the global contract research organization PPD (now Thermo Fisher Scientific) and later served as CMO for Eliem Therapeutics. She has also served as an expert consultant to several other early-stage neurology companies and on scientific advisory boards.
Solaxa’s Founder and Chief Executive Officer, Christian Walker, noted that “We are thrilled to have Dr. Chappell join the company as our Chief Medical Officer. Her experience in designing and successfully completing clinical trials that have led to novel treatments for neurological conditions will enable Solaxa to accelerate its clinical development programs.”
About Solaxa
Solaxa is a clinical-stage biopharmaceutical public benefit corporation developing treatments that restore nerve function in patients with rare neurodegenerative diseases and acute nerve injuries. The company is developing a class of aminopyridine drugs that both detect and treat ion channel dysfunction. Solaxa’s public benefit mission is to advance scientific knowledge and deliver impactful and accessible therapies that improve outcomes for patients worldwide. For more information, visit Solaxa.com.
CONTACT:
Luis Gutierrez, COO
Solaxa Inc.